1 Junior Resident, Department of General Medicine, School of Medical Science and Research, Sharda University, Greater Noida. Email: avisxn@gmail.com
2* HOD and Professor, Department of General Medicine, School of Medical Science and Research, Sharda University, Greater Noida (Corresponding Author)
Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory disorder associated with significant morbidity and cardiovascular complications. Troponin I, a sensitive biomarker of myocardial injury, has been found elevated in COPD patients, reflecting underlying cardiac stress and disease severity.
Method
This hospital-based observational study was conducted on diagnosed COPD patients. Clinical evaluation, spirometry-based GOLD staging, and laboratory investigations including serum Troponin I levels were performed. Patients were categorized based on disease severity, and associations between Troponin I levels and clinical parameters such as exacerbations, hospital stay, and outcomes were analyzed.
Result
Elevated Troponin I levels were observed in a significant proportion of COPD patients and showed a positive association with increasing disease severity (higher GOLD stages). Patients with raised Troponin I had longer hospital stays, increased frequency of exacerbations, and higher need for intensive care support. A significant correlation was also found between Troponin I levels and pulmonary function impairment, showing worsening clinical status.
Conclusion
Troponin I is a valuable biomarker for assessing disease severity and predicting clinical outcomes in COPD patients. Its elevation reflects underlying myocardial stress and can aid in early risk stratification and management.
Keywords: COPD; Troponin I; GOLD stage; myocardial injury; exacerbation; hospital stay; prognosis
How to cite this article: Saxena A, Sharma D. Assessment of Troponin I Level and Its Association with Severity of Chronic Obstructive Pulmonary Disease. Int J Drug Deliv Technol. 2026;16(21s): 532-536. DOI: 10.25258/ijddt.16.21s.56
Source of support: Nil.
Conflict of interest: Nil.